Adding CNVs and Fusions to a Lung cfDNA Assay: Impact on Oncology Clinical Research

March 27, 2018

Adding CNVs and Fusions to a Lung cfDNA Assay: Impact on Oncology Clinical Research

Genome Webinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, discusses her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.

Breaking News

Featured White Papers

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Mar

21

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison (Part 2): Best NGS Approaches for Human Transcriptome Sequencing

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Apr

09

Featured Webinar

Combining AI with Community-Driven Insights: Advanced Diagnosis of Inherited Cardiac Diseases

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies.

Main menu